« Return to News | Clinical Intelligence

Singapore develops its first cancer drug

Thursday, March 17, 2011 01:27 PM

Singapore has developed its first cancer drug, SB-939, from two Singapore-based cancer institutes and a biotechnology company, S*BIO, according to Channel News Asia.   The Singapore National University Cancer Institute, the Cancer Institute of Singapore and S*BIO have collaborated for the phase I trials.

For over a year, the drug was administered orally to 30 cancer patients three times a week.  Of these, 24 tolerated the drug well and four showed better than expected tumor growth control.

Associate Professor Goh Boon Cher, senior consultant of the Singapore National University Cancer Institution, said, "the drug actually works by causing cancer cells to die preferentially over the normal cells. So there is some selective advantage to killing cancer."

"The main side effect was tiredness and some patients who had a lower platelet count. There were some insignificant abnormalities in electrocardiograms. In general, these side effects were tolerable, reversible and did not harm the patients,” said Goh.

Phase I assessed the safety and tolerability of the drug and served to set the dosage for the phase II trials.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.